Prospective Study on Non-alcoholic Fatty Liver Disease Risk in Adults With Type 2 Diabetes Assessing DapagliflozinPioglitazone Combination Therapy

What this Trial Is About

Researchers are studying patients with type 2 diabetes to identify the risk of developing non-alcoholic fatty liver disease NAFLD during regular clinical care. The study also aims to evaluate how useful a combination therapy of Dapagliflozin and Pioglitazone is in managing these patients. This observational study is sponsored by Boryung Pharmaceutical Co., Ltd and focuses on real-world treatment effects. Participants are patients with type 2 diabetes who are beginning treatment with a fixed-dose combination of Dapagliflozin and Pioglitazone at the start of the study. The study monitors these patients over time without assigning different interventions or placebo groups, observing the natural course and treatment outcomes. Participants will be assessed for NAFLD risk using a simple scoring system at the start of the study. The main measurement is the percentage of patients who have a high risk score for NAFLD. Researchers will collect clinical data and follow patients health during their routine care to understand the relationship between type 2 diabetes, treatment, and liver health. The total duration and specific visit schedules are not detailed.

A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy